LeMaitre Vascular (LMAT) Q2 FY26 earnings call

LeMaitre Vascular delivered robust organic growth in Q2, primarily fueled by strong Artegraft performance and international expansion, despite facing currency headwinds, Middle East conflict impacts, and supply constraints for cardiac allografts. The company is actively investing in global infrastructure and sales force expansion, while navigating regulatory pathways for key products and addressing supply chain challenges to support future growth.